


CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No.	
Applicant(s): Bamford et al.			P33159USw	
Application No. 10/539,385	Filing Date June 16, 2005	Examiner	Customer No. 23347	Group Art Unit
Invention: BENZAZINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS				
<p>I hereby certify that this <u>Supplemental IDS and PTO1449 along with 35 references</u> (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>October 17, 2005</u> (Date)</p> <p><u>Patty Wilson</u> (Typed or Printed Name of Person Mailing Correspondence)</p> <p><u>Patty Wilson</u> (Signature of Person Mailing Correspondence)</p>				
<p>Note: Each paper must have its own certificate of mailing.</p>				



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of BAMFORD et al.

Serial No.: 10/539,385

Filing Date: June 16, 2005

For: Benzazepine Derivatives for the Treatment of Neurological Disorders

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))
- ☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450" under 37 CFR 1.8(a) on 10/17/2005


Patty Wilson
Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.


Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: Oct. 17, 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO. 10/539,385	
FILING DATE June 16, 2005				APPLICANT Bamford et al.	
GROUP 				EXAMINER 	
ATTORNEY DOCKET NO. P33159USw					





U.S. PATENT DOCUMENTS							
Examiner Initials	Serial No.	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	32.	4,843,081	6/27/1989	Regan et al.			
	33.	4,959,374	9/25/1900	Berge			
	34.	5,175,157	12/29/1992	Psiorz e al.			

FOREIGN PATENT DOCUMENTS							
	Serial No.	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	35.	195 30 996	2/27/1997	DE			abstract only
	36.	44 29 079	2/22/1996	DE			abstract only
	37.	1 148 054	10/24/2001	EP			
	38.	0292 840	11/30/1988	EP			abstract only
	39.	0 382 628	5/4/1994	EP			abstract only
	40.	487 071	7/5/1995	EP			
	41.	0 634 401	8/13/1997	EP			
	42.	5 239024	9/17/1993	JP			abstract only
	43.	WO 93/03015	2/18/1993	PCT			
	44.	WO 93/04686	3/18/1993	PCT			
	45.	WO 93/10089	5/27/1993	PCT			abstract only
	46.	WO 93/16997	9/2/1993	PCT			
	47.	WO 94/19315	9/1/1994	PCT			
	48.	WO 98/06701	2/19/1998	PCT			
	49.	WO 98/31356	7/23/1998	PCT			
	50.	WO 99/25709	5/27/1999	PCT			
	51.	WO 99/26919	3/6/1999	PCT			abstract only
	52.	WO 99/28314	6/10/1999	PCT			
	53.	WO 99/38862	8/5/1999	PCT			
	54.	WO 99/42462	8/26/1999	PCT			
	55.	WO 99/54310	10/28/1999	PCT			abstract only
	56.	WO 00/06254	2/10/2000	PCT			
	57.	WO 00/08022	2/17/2000	PCT			
	58.	WO 00/23437	4/27/2000	PCT			abstract only
	59.	WO 00/78724	12/28/2000	PCT			
	60.	WO 01/34571	5/17/2001	PCT			
	61.	WO 01/55118	8/2/2001	PCT			abstract only
	62.	WO 01/85695	11/15/2001	PCT			
	63.	WO 02/40451	5/23/2002	PCT			
	64.	WO 03/41641	5/22/2003	PCT			
	65.	WO 03/91258	11/6/2003	PCT			
	66.	WO 03/86306	10/23/2003	PCT			
	67.	WO 04/026305	4/1/2004	PCT			

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.